65 related articles for article (PubMed ID: 38528476)
1. Efficacy and tolerability of 100 mg of lasmiditan for migraine: A multi-center, prospective observational real-world study in Japan.
Ishii R; Ishizuchi K; Watanabe N; Fukazawa R; Trivedi M; Nakahara J; Takizawa T
Cephalalgia; 2024 Jun; 44(6):3331024241258695. PubMed ID: 38859749
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Lasmiditan as a Secondary Treatment for Migraine Attacks after Unsuccessful Treatment with a Triptan.
Shibata Y; Sato H; Sato A; Harada Y
Neurol Int; 2024 Jun; 16(3):643-652. PubMed ID: 38921952
[TBL] [Abstract][Full Text] [Related]
3. Safety profile of lasmiditan: a retrospective post-marketing pharmacovigilance study based on the real-world data of FAERS database.
Wan X; Zhang S; Jiang C; Zhang H
Expert Opin Drug Saf; 2024 Jun; ():. PubMed ID: 38898801
[TBL] [Abstract][Full Text] [Related]
4. [Acute Therapy of Migraine: What is new?].
Heinze A; Heinze-Kuhn K; Göbel H; Göbel CH
Fortschr Neurol Psychiatr; 2024 Jun; ():. PubMed ID: 38866035
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of Lasmiditan for Acute Treatment of Migraine in Adults: A Meta-Analysis.
Maiti R; Mishra A; Puliappadamb HM; Jena M; Srinivasan A
J Clin Pharmacol; 2021 Dec; 61(12):1534-1544. PubMed ID: 34472095
[TBL] [Abstract][Full Text] [Related]
6. The 5-HT1F receptor agonist lasmiditan as a potential treatment of migraine attacks: a review of two placebo-controlled phase II trials.
Tfelt-Hansen PC; Olesen J
J Headache Pain; 2012 Jun; 13(4):271-5. PubMed ID: 22430431
[TBL] [Abstract][Full Text] [Related]
7. Long-term treatment with lasmiditan in patients with migraine: post hoc analysis of treatment patterns and outcomes from the open-label extension of the CENTURION randomized trial.
Komori M; Ozeki A; Tanji Y; Kamiki E; Krege JH; Li LQ; Suzuki S; Shibata M; Takeshima T
J Headache Pain; 2024 Mar; 25(1):43. PubMed ID: 38528476
[TBL] [Abstract][Full Text] [Related]
8. Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial.
Ashina M; Roos C; Li LQ; Komori M; Ayer D; Ruff D; Krege JH
Cephalalgia; 2023 Apr; 43(4):3331024231161745. PubMed ID: 36950929
[TBL] [Abstract][Full Text] [Related]
9. Safety Findings in Lasmiditan as a Novel Acute Treatment of Migraine in Chinese Patients: A Post Hoc Analysis of the Randomized Controlled Phase 3 CENTURION Trial.
Zhou J; Luo G; Xu Y; Yang X; Pan X; Dong Z; Zhong S; Liu H; Ji F; Yu S
Adv Ther; 2022 Nov; 39(11):5229-5243. PubMed ID: 36114949
[TBL] [Abstract][Full Text] [Related]
10. Effect of a change in lasmiditan dose on efficacy and safety in patients with migraine.
Clemow DB; Hochstetler HM; Dong Y; Hauck P; Peres MFP; Ailani J
Postgrad Med; 2021 May; 133(4):449-459. PubMed ID: 33730977
[No Abstract] [Full Text] [Related]
11. Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials.
Shapiro RE; Hochstetler HM; Dennehy EB; Khanna R; Doty EG; Berg PH; Starling AJ
J Headache Pain; 2019 Aug; 20(1):90. PubMed ID: 31464581
[TBL] [Abstract][Full Text] [Related]
12. Interim results of a prospective, randomized, open-label, Phase 3 study of the long-term safety and efficacy of lasmiditan for acute treatment of migraine (the GLADIATOR study).
Brandes JL; Klise S; Krege JH; Case M; Khanna R; Vasudeva R; Raskin J; Pearlman EM; Kudrow D
Cephalalgia; 2019 Oct; 39(11):1343-1357. PubMed ID: 31433669
[TBL] [Abstract][Full Text] [Related]
13. Treatment patterns for patients initiating novel acute migraine specific medications (nAMSMs) in the context of monoclonal antibodies (mAbs) targeting the calcitonin gene-related peptide (CGRP) pathway.
Zhou Z; Urman R; Gill K; Park AS; Vuvu F; Patel LB; Lu J; Wade RL; Frerichs L; Bensink ME
J Headache Pain; 2023 Nov; 24(1):153. PubMed ID: 37946113
[TBL] [Abstract][Full Text] [Related]
14. Emerging experimental drugs in clinical trials for migraine: observations and key talking points.
Wells-Gatnik WD; Wences Chirino TY; Onan FN; Onan D; Martelletti P
Expert Opin Investig Drugs; 2023; 32(8):761-771. PubMed ID: 37672405
[TBL] [Abstract][Full Text] [Related]
15. Global, regional, and national time trends in incidence for migraine, from 1990 to 2019: an age-period-cohort analysis for the GBD 2019.
Fan L; Wu Y; Wei J; Xia F; Cai Y; Zhang S; Miao J; Zhou Y; Liu C; Yan W; Liu D; Chen L; Wang T
J Headache Pain; 2023 Jul; 24(1):79. PubMed ID: 37391721
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
